title: A multicenter evaluation of the time-course of action of two doses of rapacuronium after early and late reversal with neostigmine.
abstract: Early reversal of rapacuronium may accelerate return of neuromuscular function. This study was designed to compare early (2 min after rapacuronium) or late (at 25% recovery of the first twitch [T1] of train-of-four) reversal of rapacuronium with neostigmine. We studied 119 subjects between the ages of 18 and 75 yr. Anesthesia was induced with fentanyl and thiopental and maintained with nitrous oxide, propofol, and fentanyl. Mechanomyographic neuromuscular monitoring was performed by using train-of-four stimulation of the ulnar nerve. Two groups received 1.5 mg/kg rapacuronium followed by neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) either at 2 min after rapacuronium bolus or at 25% T1 recovery. The other two groups received 2.0 mg/kg rapacuronium, after which neostigmine was similarly given. For each rapacuronium dose, the time from the administration of rapacuronium to the start of T1 recovery or 25% T1 recovery was significantly shorter in subjects who received the reversal 2 min after rapacuronium. However, late recovery, defined by times from administration of rapacuronium to 70%, or 80% T4/T1 recovery, was not influenced by early reversal administration. We conclude that initial recovery is accelerated by early administration of neostigmine. Time to full recovery after rapacuronium administration is, however, dose-dependent and not significantly altered by early administration of neostigmine.
  
  
  CONCLUSIONS
  "Rescue reversal," which includes the administration of neostigmine shortly after the administration of rapacuronium, may accelerate the return of spontaneous breathing (early recovery), but does not shorten the time to complete recovery of upper airway function.
authors.affiliation: Department of Anesthesiology, University of Medicine and Dentistry of New Jersey, One Cooper Plaza, Camden, NJ 08103, USA. larijage@umdnj.edu
authors.forename: G E
authors.initials: GE
authors.lastname: Larijani
authors.forename: F
authors.initials: F
authors.lastname: Donati
authors.forename: G
authors.initials: G
authors.lastname: Bikhazi
authors.forename: R
authors.initials: R
authors.lastname: Bartkowski
authors.forename: C A
authors.initials: CA
authors.lastname: Kenaan
authors.forename: B
authors.initials: B
authors.lastname: Plaud
authors.forename: M E
authors.initials: ME
authors.lastname: Goldberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology*; D003473:Neuromuscular Nondepolarizing Agents / Q000494:pharmacology*; D013997:Time Factors; D014673:Vecuronium Bromide / Q000031:analogs & derivatives / Q000494:pharmacology*
chemical_list: D003473:Neuromuscular Nondepolarizing Agents; D009388:Neostigmine; D014673:Vecuronium Bromide; C082938:rapacuronium